zanzalintinib
zanzalintinib: sourced relationships with 1 company · 25 clinical trials tracked.
zanzalintinib evidence translation
What we can confirm
25 tracked trials
What it means
What to watch
Prepared research question
How could zanzalintinib → EXEL affect its developer, and what evidence supports the link?
Traceable citations · Unknowns marked
See linked entities and source evidence8 indications · 0 study sponsors
Related indications
Study sponsors
No additional listed-company sponsor is linked.
Dated Pipeline Records (1)
| Company | Dated record stage |
|---|---|
| EXELIXIS, INC. (EXEL) Pancreatic Neuroendocrine Tumor (pNET); Renal Cell Carcinoma… | Phase 1 |
Clinical Trial Registry Records (25)showing 10 most recent
A Phase 2 Clinical Trial of Zanzalintinib in Patients With Unresectable and Progressive Metastatic Pheochromocytoma or Paraganglioma (MPPGs)
Primary endpoint: Objective Response Rate (ORR)
A Phase 2, Single-Arm, Multicenter Trial of Zanzalintinib in Combination With Pembrolizumab in First-Line Maintenance for Metastatic Squamous Non-Small Cell Lung Cancer
Primary endpoint: Progression-Free Survival (PFS) at 6 Months (PFS-6) per Response Evaluation Criteria in Solid Tumors version 1.1 (RECIST v1.1) as Assessed by Investigator
Phase II Trial of Zanzalintinib for Advanced Urothelial Carcinoma Progressing After Prior Therapy
Primary endpoint: Objective response rate (ORR)
A Phase 1 Dose-Escalation Study of XL092 in Children and Adolescents With Relapsed or Refractory Solid Tumors
Primary endpoint: Number of Participants With Dose-Limiting Toxicities (DLTs)
ZENITH: Zanzalintinib Efficacy Post Pluvicto® in Chemotherapy Naïve Metastatic Castration Resistant Prostate Cancer
Primary endpoint: Radiographic progression free survival (rPFS)
Randomized Phase 3 Study of Zanzalintinib ± Subcutaneous Pembrolizumab and Berahyaluronidase Alfa (MK-3475A) Versus Placebo in Participants With Colorectal Cancer With Stage II/III Molecular Residual Disease Following Definitive Therapy
Primary endpoint: Disease-Free Survival (DFS) in Zanzalintinib + MK-3475A Versus Placebo as Assessed by the Investigator
Phase II Study of Zanzalintinib in Men With Aggressive Variant Prostate Cancer (NAPOLEON Study)
Primary endpoint: Radiographic progression free survival (rPFS)
Long-Term Extension Study for Participants Previously Enrolled in an Exelixis-Sponsored Study
Primary endpoint: Number of Participants With Treatment Emergent Adverse Events (TEAEs)
A Phase II Study of Zanzalintinib for Metastatic Clear Cell Renal Cell Carcinoma With Bone Metastases in Patients Previously Treated With Immune Checkpoint Inhibitors
Primary endpoint: Proportion of participants who have not progressed at 12 months (PFS12)
A Phase 2, Single-Arm, Multicenter, Open-Label Study of Zanzalintinib in Participants With Recurrent or Progressive Meningioma
Primary endpoint: Objective Response Rate (ORR) per Response Assessment in Neuro-oncology (RANO) as Assessed by Blinded Independent Central Review (BICR)
Frequently asked questions
Which companies have sourced relationships with zanzalintinib?
zanzalintinib has dated SEC/FDA relationship records for EXELIXIS, INC..
How many clinical trials involve zanzalintinib?
BioSniper tracks 25 clinical trials involving zanzalintinib.